The findings suggest that blood tumor mutational burden measured by NCC-GP150 is a potential biomarker to identify patients with non–small cell lung cancer who could benefit from anti–PD-1 and anti–PD-L1 therapy. This evidence concerns the gene PDCD1 and lung cancer.